SCHEMBL3947748

SCHEMBL3947748

Cc1ccc(O)c(-c2cccnc2)n1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 5/20 0.53
CYP3A4 P08684 3/20 0.47
ALDH1A1 P00352 1/20 0.47
CYP1A2 P05177 1/20 0.47
NPY5R Q15761 1/20 0.46
CYP2E1 P05181 2/20 0.46
CYP2C9 P11712 2/20 0.46
CYP2B6 P20813 2/20 0.46
NPC1 O15118 2/20 0.44
RAB9A P51151 2/20 0.44
ATM Q13315 1/20 0.44
CYP2D6 P10635 1/20 0.44
CYP2C19 P33261 1/20 0.44
EGFR P00533 1/20 0.43
PDGFRB P09619 1/20 0.43
PDGFRA P16234 1/20 0.43
KDM4E B2RXH2 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
ERN1 O75460 1/20 0.43
ALOX5 P09917 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3894707 0.82 ALOX5 (0.43) CYP2A6CYP3A4ALDH1A1CYP1A2NPY5R
SCHEMBL30146610 0.80 KDM4E (0.46) ALDH1A1NPC1RAB9AKDM4E
SCHEMBL20124614 0.80 ALDH1A1 (0.49) CYP3A4ALDH1A1CYP2C9NPC1RAB9A
SCHEMBL6002898 0.79 CYP2A6 (0.42) CYP2A6CYP3A4ALDH1A1CYP1A2NPY5R
SCHEMBL3900693 0.77 CYP2A6 (0.51) CYP2A6CYP3A4ALDH1A1CYP1A2NPY5R
SCHEMBL29912567 0.75 CYP2A6 (0.40) CYP2A6CYP3A4ALDH1A1CYP1A2NPY5R
SCHEMBL28956971 0.75 CYP2A6 (0.40) CYP2A6CYP3A4ALDH1A1CYP1A2NPY5R
SCHEMBL4471287 0.75 CYP2A6 (0.56) CYP2A6CYP3A4ALDH1A1CYP1A2CYP2E1
SCHEMBL9356023 0.74 KDM4E (0.54) CYP3A4ALDH1A1CYP1A2CYP2C9NPC1
SCHEMBL30216796 0.74 CYP2A6 (0.61) CYP2A6CYP3A4ALDH1A1CYP1A2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250179059-A1 ANTICANCER COMPOUNDS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2025-06-05 US disclosed
US-12162870-B2 Anticancer compounds THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2024-12-10 US disclosed
US-20230025178-A1 ANTICANCER COMPOUNDS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2023-01-26 US disclosed
EP-2970173-B1 INHIBITORS OF THE KYNURENINE PATHWAY CURADEV PHARMA PRIVATE LTD (IN) 2018-05-09 EP disclosed
US-20090048269-A1 CHEMICAL COMPOUNDS-821 ASTRAZENECA AB (SE) 2009-02-19 US disclosed
WO-2009022171-A1 PYRIDINYIIOXY PYRIDINES AS ALK5 INHIBITORS ASTRAZENECA AB (SE) 2009-02-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250179059-A1 ANTICANCER COMPOUNDS BET1, BRD4, BICRA CYP2A6 4093/4885CYP3A4 3755/4885ALDH1A1 3346/4885
US-20230025178-A1 ANTICANCER COMPOUNDS BET1, BRD4, BICRA CYP2A6 4093/4885CYP3A4 3755/4885ALDH1A1 3346/4885
US-20090048269-A1 CHEMICAL COMPOUNDS-821 TGFBR1, TGFBR2, SMAD3 CYP2A6 3384/4885CYP3A4 2028/4885ALDH1A1 163/4885
US-12162870-B2 Anticancer compounds BET1, BRD4, BICRA CYP2A6 4093/4885CYP3A4 3755/4885ALDH1A1 3346/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.